Back to mobile site
Get it on Google Play

Genmab's Rina-S shows 45.9% response rate in ovarian cancer trial

October 3, 2026 3:40 PM EDT Send to a Friend
Genmab A/S (Nasdaq: GMAB) reported Phase 2 results from Part C of its RAINFOL-01 trial evaluating rinatabart sesutecan (Rina-S), an ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login